Self-expanding Centera Valve for the Treatment of severe, Symptomatic Aortic Stenosis

Abstract

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for both high and intermediate operative risk patients with severe symptomatic aortic stenosis. The number of patients undergoing TAVI has increased over the last decade warranting continued technological improvements in transcatheter heart valve (THV) systems. The novel CENTERA self-expanding THV (Edwards Lifesciences, CA, USA) received CE approval this year. It is deliverable through a 14Fr sheath and has a unique motorized delivery system. The CENTERA-2 study results demonstrated a favorable survival rate at 30 days (99%), as well as a low need for new permanent pacemaker implantation (4.9%). 1-year outcomes reported a low incidence of >moderate paravalvular leak (0.6%) and consistently favorable THV hemodynamics making this a competitive THV for patients with severe aortic stenosis.

Keywords: :

• aortic stenosis
• interventional
• valvular heart disease

Acknowledgments

We would like to acknowledge the cooperation from the team at Edwards Lifesciences for the permissions granted for the use of all tables and images displayed within this manuscript.

Financial & Competing Interest Disclosure

M Spence-Edwards Lifesciences Consultancy Edwards Lifesciences Proctor. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.